📊 IVVD Key Takeaways
Is Invivyd, Inc. (IVVD) a Good Investment?
Invivyd is a pre-commercial biotech company burning $41.7M annually against only $13.7M revenue, resulting in -301% net margins and negative free cash flow of -$42.4M. While the strong balance sheet ($184.2M cash, no debt) provides ~4.4 years of runway, the company faces fundamental profitability challenges with revenue insufficient to support current operating expenses until achieving significant commercialization.
Invivyd shows strong top-line momentum, with revenue more than doubling year over year, and its balance sheet is unusually strong for a loss-making biotech, supported by $226.69M in cash and no meaningful debt. However, growth quality remains weak because operating losses still exceed revenue, net margin is deeply negative, and free cash flow burn remains substantial. The company has enough liquidity to keep executing, but fundamentals still depend on proving that revenue growth can translate into materially better margins and lower cash burn.
Invivyd, Inc. Key Strengths (IVVD)
- Strong balance sheet with $184.2M cash and zero debt, providing financial flexibility
- Excellent liquidity ratios (Current: 6.47x, Quick: 6.32x) ensuring near-term solvency
- Revenue growing rapidly at +110.5% YoY, indicating early product-market traction
- Revenue grew 110.5% year over year, indicating meaningful commercial traction
- Cash and equivalents of $226.69M with no long-term debt provide strong financial flexibility
- Liquidity is very strong, with current and quick ratios above 7x
IVVD Stock Risks: Invivyd, Inc. Investment Risks
- Severe unprofitability with -301% net margin and operating losses of -$43.1M
- Negative operating cash flow of -$41.7M annually with free cash flow of -$42.4M
- Revenue base of $13.7M is minimal relative to burn rate; profitability timeline unclear
- Operating margin of -104.0% shows the business is still not economically self-sustaining
- Free cash flow of -$58.29M indicates continued heavy cash burn despite revenue growth
- Net margin of -98.2% suggests current growth has not yet converted into durable profitability
Key Metrics to Watch
- Quarterly cash burn rate and remaining runway sustainability
- Revenue growth acceleration and gross margin development
- Path to operating profitability and clinical/commercialization milestones
- Operating cash burn and free cash flow trend
- Operating margin improvement relative to revenue growth
Invivyd, Inc. (IVVD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.47x current ratio provides a solid financial cushion.
IVVD Profit Margin, ROE & Profitability Analysis
IVVD vs Healthcare Sector: How Invivyd, Inc. Compares
How Invivyd, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Invivyd, Inc. Stock Overvalued? IVVD Valuation Analysis 2026
Based on fundamental analysis, Invivyd, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Invivyd, Inc. Balance Sheet: IVVD Debt, Cash & Liquidity
IVVD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Invivyd, Inc.'s revenue has grown significantly by 110% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.43 indicates the company is currently unprofitable.
IVVD Revenue Growth, EPS Growth & YoY Performance
IVVD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $11.3M | -$16.3M | $-0.13 |
| Q3 2025 | $9.3M | -$10.5M | $-0.06 |
| Q2 2025 | $2.3M | -$14.7M | $-0.12 |
| Q1 2025 | N/A | -$16.3M | $-0.14 |
| Q3 2024 | N/A | -$35.3M | $-0.36 |
| Q2 2024 | N/A | -$35.3M | $-0.40 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Invivyd, Inc. Dividends, Buybacks & Capital Allocation
IVVD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Invivyd, Inc. (CIK: 0001832038)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IVVD
What is the AI rating for IVVD?
Invivyd, Inc. (IVVD) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 71% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IVVD's key strengths?
Claude: Strong balance sheet with $184.2M cash and zero debt, providing financial flexibility. Excellent liquidity ratios (Current: 6.47x, Quick: 6.32x) ensuring near-term solvency. ChatGPT: Revenue grew 110.5% year over year, indicating meaningful commercial traction. Cash and equivalents of $226.69M with no long-term debt provide strong financial flexibility.
What are the risks of investing in IVVD?
Claude: Severe unprofitability with -301% net margin and operating losses of -$43.1M. Negative operating cash flow of -$41.7M annually with free cash flow of -$42.4M. ChatGPT: Operating margin of -104.0% shows the business is still not economically self-sustaining. Free cash flow of -$58.29M indicates continued heavy cash burn despite revenue growth.
What is IVVD's revenue and growth?
Invivyd, Inc. reported revenue of $13.7M.
Does IVVD pay dividends?
Invivyd, Inc. does not currently pay dividends.
Where can I find IVVD SEC filings?
Official SEC filings for Invivyd, Inc. (CIK: 0001832038) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IVVD's EPS?
Invivyd, Inc. has a diluted EPS of $-0.13.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is IVVD's fundamental grade?
Based on our AI fundamental analysis in June 2026, Invivyd, Inc. has a C grade with 71% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is IVVD stock overvalued or undervalued?
Valuation metrics for IVVD: ROE of -20.4% (sector avg: 15%), net margin of -301.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is IVVD's AI grade for 2026?
Our dual AI analysis gives Invivyd, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IVVD's free cash flow?
Invivyd, Inc.'s operating cash flow is $-41.7M, with capital expenditures of $726.0K. FCF margin is -308.8%.
How does IVVD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -301.2% (avg: 12%), ROE -20.4% (avg: 15%), current ratio 6.47 (avg: 2).